Advanced SearchSearch Tips
Neuropeptide Y protects kidney against cisplatin-induced nephrotoxicity by regulating p53-dependent apoptosis pathway
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : BMB Reports
  • Volume 49, Issue 5,  2016, pp.288-292
  • Publisher : Korean Society for Biochemistry and Molecular Biology
  • DOI : 10.5483/BMBRep.2016.49.5.231
 Title & Authors
Neuropeptide Y protects kidney against cisplatin-induced nephrotoxicity by regulating p53-dependent apoptosis pathway
Kim, Namoh; Min, Woo-Kie; Park, Min Hee; Lee, Jong Kil; Jin, Hee Kyung; Bae, Jae-sung;
  PDF(new window)
Cisplatin is a platinum-based chemotherapeutic drug for treating various types of cancers. However, the use of cisplatin is limited by its negative effect on normal tissues, particularly nephrotoxicity. Various mechanisms such as DNA adduct formation, mitochondrial dysfunction, oxidative stress, and apoptosis are involved in the adverse effect induced by cisplatin treatment. Several studies have suggested that neuropeptide Y (NPY) is involved in neuroprotection as well as restoration of bone marrow dysfunction from chemotherapy induced nerve injury. However, the role of NPY in chemotherapy-induced nephrotoxicity has not been studied. Here, we show that NPY rescues renal dysfunction by reducing the expression of pro-apoptotic proteins in cisplatin induced nephrotoxicity through Y1 receptor, suggesting that NPY can protect kidney against cisplatin nephrotoxicity as a possible useful agent to prevent and treat cisplatin-induced nephrotoxicity.
Apoptosis;Chemotherapy-induced side effect;Cisplatin;Nephrotoxicity;Neuropeptide Y;
 Cited by
Pabla N and Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73, 994-1007 crossref(new window)

Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 crossref(new window)

Pabla N, Dong G, Jiang M et al (2011) Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 121, 2709-2722 crossref(new window)

Jia Z, Wang N, Aoyagi T, Wang H, Liu H and Yang T (2011) Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int 79, 77-88 crossref(new window)

Oh GS, Kim HJ, Choi JH et al (2014) Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int 85, 547-560 crossref(new window)

Sah R and Geracioti TD (2013) Neuropeptide Y and posttraumatic stress disorder. Mol Psychiatry 18, 646-655 crossref(new window)

Santos-Carvalho A, Elvas F, Alvaro AR, Ambrósio AF and Cavadas C (2013) Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis 4, e636 crossref(new window)

Körner M, Waser B and Reubi JC (2004) Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 84, 71-80 crossref(new window)

Gonçalves J, Ribeiro CF, Malva JO and Silva AP (2012) Protective role of neuropeptide Y Y2 receptors in cell death and microglial response following methamphetamine injury. Eur J Neurosci 36, 3173-3183 crossref(new window)

Park MH, Jin HK, Min WK et al (2015) Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow. EMBO J 34, 1648-1660 crossref(new window)

Humanes B, Lazaro A, Camano S et al (2012) Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 82, 652-663 crossref(new window)

Panesso MC, Shi M, Cho HJ et al (2014) Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int 85, 855-870 crossref(new window)

Linkermann A, Himmerkus N, Rölver L et al (2011) Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int 79, 169-178 crossref(new window)

Jiang M, Yi X, Hsu S, Wang CY and Dong Z (2004) Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287, F1140-1147 crossref(new window)

Xu Y, Ma H, Shao J et al (2015) A Role for Tubular Necroptosis in Cisplatin-Induced AKI. J Am Soc Nephrol 26, 2647-2658 crossref(new window)

Lim SW, Jin L, Piao SG, Chung BH et al (2015) Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury. Lab Invest 95, 1174-1185 crossref(new window)

Katagiri D, Hamasaki Y, Doi K et al (2013) Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 24, 2034-2043 crossref(new window)

Smiałowska M, Domin H, Zieba B et al (2009) Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 43, 235-249 crossref(new window)

Wei Q, Dong G, Franklin J and Dong Z (2007) The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72, 53-62 crossref(new window)

Hwang HS, Park IY, Kim DW et al (2015) PEP-1-FK506BP12 inhibits matrix metalloproteinase expression in human articular chondrocytes and in a mouse carrageenan-induced arthritis model. BMB Rep 48, 407-412 crossref(new window)

Hu L, Su P, Li R et al (2015) Knockdown of microtubule actin crosslinking factor 1 inhibits cell proliferation in MC3T3-E1 osteoblastic cells. BMB Rep 48, 583-588 crossref(new window)